Objectives 
Introduction

Chronic hepatitis (CH) C infection can be associated with progressive liver disease that may evolve insidiously into liver cirrhosis and carries an increased risk of hepatocellular carcinoma (HCC) (1). The majority of deaths due to HCC are ascribed to hepatitis viruses, of which 70-80% corresponding to approximately 30,000 per year is attributed to the persistent infection with HCV in Japan (2, 3). Thus, it is important to eradicate HCV-RNA or decrease levels of alanine aminotransferase (ALT) for preventing HCC with interferon (IFN) therapy
. Recently, it has been reported that novel long-acting formulations of IFN known as induce higher eradication rate of HCV (6) (7) (8) .
However, IFN therapy has been associated with various IFN-related adverse events. The onset of interstitial pneumonia (IP) has been reported when HCV positive patients were given IFN (9) (10) (11) . Moreover, Karim et al (12) We selected patients in chronological order in groups of 25 from the first to the third groups described above. These patients were consecutively selected when they had the following criteria: 1) positivity for HCV-RNA by amplicor monitor assay (16) (20) . T a b l e 1 . Cl i n i c a l Ch a r a c t e r i s t i c s o f t h e P a t i e n t s E n r o l l 
Materials and Methods
Patients
Statistical analysis
Clinical differences among three groups before follow-up were assessed by the Kruskal Wallis test. Changes in serum
Results
Pretreatment clinical characteristics
Two of 25 patients treated with combination of pegylated IFN and ribavirin dropped out from this clinical study owing to IFN-related adverse effect of depression and general
Factors contributing to the elevated serum KL-6 level
Six of 73 patients showed an elevated serum KL-6 level of more than 450 U/ml. 
Discussion
Serum KL-6 levels are generally increased in patients with fibrosing lung infection (13, 14) . However, serum levels of KL-6 are sometimes elevated in patients with certain malignancies such as adenocarcinoma of the lung, breast, pancreas and HCC (21, 22) . In the present study, none of the patients had malignancies for two years after the initiation of follow-up. Therefore, we think that changes in the serum KL-6 level in the present study were not related to malignancies.
The present study indicates the following. First, serum levels of KL-6 in HCV-positive patients untreated remained stable during follow-up. Second, the serum levels of KL-6 in patients treated with combination of pegylated IFN and ribavirin were significantly increased compared to those of pretreatment. About 20% of patients treated with combination therapy of pegylated IFN and ribavirin showed an ele-F i g u r e 1 . Ch a n g e o v e r t i me i n s e r u m KL -6 l e v e l s c o mp a r e d wi t h p r e t r e a t me n t v a l u e s i n c h r o n i c h e p a t i t i s C p a t i e n t s r e c e i v i n g e a c h t r e a t me n t . Ch a n g e s a r e e x p r e s s e d a s me a n p e r c e n t a g e s ± s t a nd a r d d e v i a t i o n o f p r e t r e a t me n t b a s e l i n e v a l u e s f o r e a c h g r o u p . * S e r u m KL -6 l e v e l s o f g r o u p t r e a t e d wi t h c o mb i n a t i o n t h e r a p y o f p e g y l a t e d I F N a n d r i b a v i r i n we r e s i g n i f i c a n t l y g r e a t e r c o mp a r e d t o t h a t o f p r e t r e a t me n t ( P < 0 . 0 5 ) . a P = c o mp a r i s o n o f KL -6 l e v e l b e t we e n p a t i e n t s t r e a t e d wi t h p e g y l a t e d I F N a n d r i b a v i r i n a n d u n t r e a t e d . 
b P = c o mp a r i s o n o f KL -6 l e v e l b e t we e n p a t i e n t s t r e a t e d wi t h I F N mo n o t h e r a p y a n d u n t r e a t e d .
T a b l e 2 . Di f f e r e n c e o f B a c k g r o u n d s b e t we e n E l e v a t e d KL -6 Gr o u p a n d Un el e v a t e d Gr
Conclusion
The present study indicates that the onset of interstitial pneumonia should be carefully checked in the combination therapy of pegylated-IFN and ribavirin.
